|
 Pipeline
ARD-3100/3150/1100
(Pulmaquin®, Lipoquin®)
ARD-1600
Other Applications
Scientific Publications
|
Inhalation Drug Treatments to Prevent and Treat Severe
Respiratory Diseases
Inhalation
drug delivery is the preferred method of treatment for many respiratory
diseases and it is gaining acceptance as a route of delivery for the
treatment of systemic diseases. Currently, Aradigm has respiratory inhalation
products in preclinical and clinical development for the treatment of
cystic fibrosis, bronchiectasis*, biodefense and tobacco smoking cessation.
These products are designed to improve patients' quality of life and
overall treatment outcomes by enabling them to safely and painlessly
self-administer aerosolized liquid medications directly to and through the
lungs. All of these products utilize the Company's proprietary drug
delivery technologies.
Below is
a list of proprietary programs and their respective stages of development.
In addition to these current programs, Aradigm continues to apply its
expertise and intellectual property to other potential therapeutic
applications that may benefit from the Company's novel formulations and
drug delivery technology.
|
 Proprietary Programs
|
|
|
|
|
|
Product /
Indication
|
Research
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
New Drug
Application
|
FDA
Approved
|
|
|
|
|
|
ARD-3150 Bronchiectasis* (BE)
|
|
|
Liposomal
|
|
|
|
|
|
|
|
|
|
Ciprofloxacin
|
|
|
|
|
|
|
|
|
|
|
|
|
ARD-3100 Cystic Fibrosis (CF)
|
|
|
Liposomal
|
|
|
|
|
|
|
|
|
|
Ciprofloxacin
|
|
|
|
|
|
|
|
|
|
|
|
|
ARD-1100 Biodefense
(inhalational tularemia, pneumonic plague, Q-fever)
|
|
|
Liposomal
|
|
|
|
|
|
|
|
|
|
Ciprofloxacin
|
|
|
|
|
|
|
|
|
|
|
|
|
ARD-1600 Smoking Cessation
|
|
|
Nicotine
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* If you
would like to see a video explaining what bronchiectasis is, please, click
on this icon:
|
